Mintz team displays cross-disciplinary expertise in life sciences sector with newly combined company

Mintz served as legal counsel to Boston-based NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on multimodal, disease-modifying therapies for neurodegenerative diseases, in its recently completed merger with Livonia, Michigan-based Gemphire Therapeutics (Gemphire; Nasdaq: GEMP), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of dyslipidemia as well as nonalcoholic fatty liver disease. The transaction closed on December 31, 2019.

As part of the merger, the newly combined company, known as NeuroBo Pharmaceuticals, Inc. (NeuroBo), began trading on the Nasdaq stock exchange under the ticker symbol “NRBO.” NeuroBo will focus on advancing the company’s clinical-stage pipeline for neurodegenerative diseases, including its lead product candidate, NB-01, targeting neuropathic pain, as well as NB-02, targeting Alzheimer’s disease and tauopathies. In addition, NeuroBo plans to continue the advancement of gemcabene, which has been in development by Gemphire for the treatment of dyslipidemia.

The Mintz team representing NeuroBo was led by Members Megan Gates, Marc Mantell, and Bill Whelan, with assistance from Brian Shea, Avi Reshtick, Nancy Adams, Robert Kidwell, Joanne Hawana, Terri Shieh-Newton, John Cheney, Jessica Catlow, David Lagasse, Breton Leone-Quick, Patricia Moran, Anne Bruno, Farrah Short, Laura Stacey, Flora Brookfield, Melanie Levy, Zane Polston, Amanda Mei, David Salamon, Samantha Silver, Alexander Song, and Evelyne Guillouet. Ms. Gates is the Co-Chair of the firm’s Securities and Capital Markets Practice Group and Mr. Whelan is the Co-chair of the firm’s Life Sciences Practice.

Mintz is one of the leading law firms to the life sciences industry. The firm’s attorneys advise hundreds of businesses and other organizations across the sector’s ecosystem—from start-ups and emerging growth companies to large public companies as well as venture capital firms, investment banks, and research and academic institutions—on pivotal deals, mission-critical disputes, intellectual property, and regulatory matters.